A Better Approach, for 
Better Breast Cancer Trials

Breast cancer affects more women worldwide than any other cancer. Despite its prevalence, studying and improving treatment is extremely complex. Oncology studies often involve multiple cohorts, tumor types, scattered sites, and expensive medications. More importantly, breast cancer patients face debilitating symptoms that can make participation in studies difficult. That's where Signant's evidence generation solutions and deep oncology experience can help.

CONNECT WITH US đź –
 

We Have Solutions to Help Your Study Succeed

Capture Accurate Data & Incorporate PROMS

Leverage our leading digital solutions as well as extensive clinical and eCOA science expertise to capture high-quality, reliable endpoint data. And with our deep understanding of recent FDA guidance on the use of patient-reported outcomes in oncology trials, we're prepared to help you incorporate patients' perspectives in your data capture strategy. 

Gain Richer Insights

With our sensors and wearables, you can collect objective data on sleep and activity patterns, for enhanced insight into the post-treatment recovery associated with each treatment cycle. Pair with our eCOA for a continuous, real-time view of each patients’ health status.

Optimize Supply Management

Our Signant SmartSignals RTSM solution uses proprietary algorithms to optimize drug supplies for the different, complex study designs associated with breast cancer trials, and applies randomization adaptations seamlessly.

Digitalize the Entire Process

While all of our solutions can be used as standalone tools, they seamlessly integrate with one another to further enhance the accuracy and efficiency of your breast cancer study.

Signant SmartSignals eConsent uses engaging multimedia to convey complex information and allows patients to flag sections they have questions on. The solution also handles the multiple consents and protocol amendments common in breast cancer trials, limiting the risk of inspection findings.

Simplify the Consent Process

Place the Patient First

Our patient-focused approach is embedded in everything from the software to the eCOA instruments’ overall designs. For example, thoughtfully migrating instrument layouts to electronic formats to ensure ease of use, such as larger, well-spaced buttons compensate for treatment-related finger numbness.

COUNTRIES

71

76,000+

PATIENTS

18,600

SITES

STUDIES

78

I - IV

PHASES

Our Breast Cancer
Experience by the Numbers

 

Breast Cancer Solutions

Breast Cancer Trial Solution Resources

DOWNLOAD

Signant's Subject Matter Experts

MEET THE EXPERTS

Breast Cancer Trial Solutions

WATCH VIDEO

Enhance Your Breast Cancer Clinical Trials with Signant

PATIENT CONCIERGE

RTSM

eCOA

eCONSENT

LEARN MORE đź –LEARN MORE đź –LEARN MORE đź –LEARN MORE đź –

READY TO GET STARTED?

See how Signant can support your next breast cancer clinical trial.

CONNECT WITH US

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at  www.signanthealth.com.